TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17059386

Group type: EXPERIMENTAL
Intervention: Randomised Phase III trials
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Selected Phase I and II studies
Number of subjects: 3700

Group type: EXPERIMENTAL
Intervention: Interesting studies on hot topics
Number of subjects: 3700
Study: 15448446

Group type: EXPERIMENTAL
Intervention: 1 sacroiliac screw in the vertebral body of S1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 screws convergingly in S1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1 screw in S1 and 1 in S2
Number of subjects: 12
Study: 11457627

Group type: EXPERIMENTAL
Intervention: Five-session group intervention focused on strategies for practicing safer sexual behavior
Number of subjects: 332

Group type: COMPARATOR
Intervention: Five-session, contact-matched, health-maintenance support group (standard-of-care comparison)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Behavioral risk-reduction intervention group
Number of subjects: 332
Study: 9893539

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 1 mg.kg‐1 (T1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 2 mg.kg‐1 (T2)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravenous pethidine 1 mg.kg‐1 (PE)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 88
Study: 8008364

Group type: EXPERIMENTAL
Intervention: Intraoperative suture adjustment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intraoperative suture adjustment)
Number of subjects: 25
Study: 2646257

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus hyperthermia (RT + HT)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RT + HT in lesions less than 3 cm
Number of subjects: 218

Group type: COMPARATOR
Intervention: RT alone in lesions less than 3 cm
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RT + HT in breast lesions
Number of subjects: 218

Group type: COMPARATOR
Intervention: RT alone in breast lesions
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RT + HT in trunk and extremities lesions
Number of subjects: 218

Group type: COMPARATOR
Intervention: RT alone in trunk and extremities lesions
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RT + HT in lesions larger than 3 cm
Number of subjects: 218

Group type: COMPARATOR
Intervention: RT alone in lesions larger than 3 cm
Number of subjects: 218
Study: 4606495

Group type: EXPERIMENTAL
Intervention: Neomycin and tetracycline (group 2)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Neomycin (group 1)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 196
Study: 29169902

Group type: EXPERIMENTAL
Intervention: ACTIVA'T group (nutritional and physical activity ≥5h/wk intervention)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (nutritional intervention and ≤3h/wk physical activity)
Number of subjects: 96
Study: 29267375

Group type: EXPERIMENTAL
Intervention: Standard versus New Antiepileptic Drugs (SANAD) treatment
Number of subjects: 0
Study: 26648705

Group type: EXPERIMENTAL
Intervention: Specific strength training group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual PR program group
Number of subjects: 60
Study: 23390177

Group type: EXPERIMENTAL
Intervention: Verum stimulation (Cefaly, STX‐Med., Herstal, Belgium) applied daily for 20 minutes for 3 months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Verum stimulation
Number of subjects: 67
Study: 22005160

Group type: EXPERIMENTAL
Intervention: Rapid initiation of quetiapine (up to 800 mg/d by Day 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional initiation of quetiapine (up to 400 mg/d by Day 5)
Number of subjects: 40
Study: 19200399

Group type: EXPERIMENTAL
Intervention: Supervised multi-modal exercise therapy programme
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Individualised manual therapy programme
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both exercise therapy and manual therapy
Number of subjects: 224

Group type: COMPARATOR
Intervention: No trial physiotherapy (control)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Usual care alone (control)
Number of subjects: 224
Study: 16970536

Group type: EXPERIMENTAL
Intervention: Flexion Distraction
Number of subjects: 235

Group type: COMPARATOR
Intervention: Exercise Program
Number of subjects: 235
Study: 15164336

Group type: EXPERIMENTAL
Intervention: Egg diet (640 mg/d additional dietary cholesterol)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo diet (0 mg/d additional dietary cholesterol)
Number of subjects: 52
Study: 11240880

Group type: EXPERIMENTAL
Intervention: Diclofenac 1-2 mg.kg-1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acetaminophen 22.5 mg.kg-1
Number of subjects: 21
Study: 9240263

Group type: COMPARATOR
Intervention: Intact germinal vesicle with cumulus (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intact germinal vesicle with sperm cells (Group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stripped germinal vesicle (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stripped germinal vesicle with sperm cells (Group 4)
Number of subjects: 80
Study: 8494126

Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 29
Study: 3682574

Group type: EXPERIMENTAL
Intervention: reserpin (0.5‐0.75 mg/day)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: dopegyt (750‐1500 mg/day)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: clophelin (0.3‐0.6 mg/day)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: anaprilin (80‐160 mg/day)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (25‐100 mg/day)
Number of subjects: 294

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 294
Study: 29900819

Group type: EXPERIMENTAL
Intervention: Aquablation
Number of subjects: 90

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 90
Study: 28687830

Group type: EXPERIMENTAL
Intervention: Cetuximab added to weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions.
Number of subjects: 328

Group type: COMPARATOR
Intervention: Weekly concurrent cisplatin (50 mg/m2), paclitaxel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions without cetuximab.
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Cetuximab added to concurrent chemoradiation.
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control group (no cetuximab).
Number of subjects: 328
Study: 25385096

Group type: EXPERIMENTAL
Intervention: Primaquine alone (30 mg base)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Pyronaridine-artesunate alone (540-180 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate plus primaquine
Number of subjects: 17
Study: 23266402

Group type: EXPERIMENTAL
Intervention: Nebulized Dornase alfa administered twice daily until extubation, death, or transfer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo administered twice daily until extubation, death, or transfer
Number of subjects: 30
Study: 21252053

Group type: EXPERIMENTAL
Intervention: Computer-generated reminders with printed summaries for overdue CD4 tests
Number of subjects: 717

Group type: COMPARATOR
Intervention: Control clinic without reminders
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Computer-generated reminders (regardless of printed summaries)
Number of subjects: 717

Group type: EXPERIMENTAL
Intervention: Printed summaries with reminders
Number of subjects: 717
Study: 18379765

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 17000366

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: D-dimer greater than 4.1 mmol/L
Number of subjects: 300
Study: 12921250

Group type: EXPERIMENTAL
Intervention: Neural network
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bayesian approach
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Forward stepwise regression LSM
Number of subjects: 55
Study: 10937110

Group type: EXPERIMENTAL
Intervention: Shaved eyebrow
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unshaven eyebrow (control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Shaved eyebrow (specific case)
Number of subjects: 5
Study: 8682466

Group type: EXPERIMENTAL
Intervention: Combined locoregional immuno-chemotherapy (Group B)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Locoregional chemotherapy (Group A)
Number of subjects: 48
Study: 1868748

Group type: EXPERIMENTAL
Intervention: Naftifine gel 1 percent applied twice daily for four weeks
Number of subjects: 316

Group type: COMPARATOR
Intervention: Gel vehicle applied twice daily for four weeks
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Naftifine gel 1 percent
Number of subjects: 316
Study: 6922161

Group type: EXPERIMENTAL
Intervention: Behavioral orientation to infant's behavior (Group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Behavioral orientation to infant's behavior (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unpretested mothers (Group III)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group IV)
Number of subjects: 40
Study: 30985379

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (0 µg/kg)
Number of subjects: 64
Study: 29724499

Group type: COMPARATOR
Intervention: Placebo TID
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg TID
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 500 mg TID
Number of subjects: 135
Study: 26950696

Group type: EXPERIMENTAL
Intervention: Water provision (bottle of drinking water that could be refilled throughout the day)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control (access to drinking water normally available at the school)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Water provision and hydration
Number of subjects: 292
Study: 24281785

Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 197
Study: 22189260

Group type: EXPERIMENTAL
Intervention: Exposure to starchy table foods (yes)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Exposure to fruit table food (no)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Eating starchy table foods at 6 months
Number of subjects: 61
Study: 21035187

Group type: EXPERIMENTAL
Intervention: KEEP parenting program (intervention)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: PDR ratings (intervention)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Parent-reported stress (intervention)
Number of subjects: 359
Study: 17333382

Group type: EXPERIMENTAL
Intervention: Healthy Relationships intervention (HR-A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Relationships intervention (HR-O)
Number of subjects: 0
Study: 11139861

Group type: EXPERIMENTAL
Intervention: Maternity gel pads
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ice packs and Epifoam
Number of subjects: 120
Study: 9132351

Group type: EXPERIMENTAL
Intervention: Subcutaneous Redon drains
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drains (Control)
Number of subjects: 100
Study: 8351157

Group type: EXPERIMENTAL
Intervention: Desipramine for 7 days pre-operatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine for 3 days starting 7 days before surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine for 3 days starting 3 days pre-operatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3523240

Group type: EXPERIMENTAL
Intervention: Oral rifampin given for five days
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full course of rifampin
Number of subjects: 0
Study: 29258789

Group type: EXPERIMENTAL
Intervention: Mepolizumab treatment
Number of subjects: 1192
Study: 26670576

Group type: EXPERIMENTAL
Intervention: MiniArc (single-incision midurethral sling)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Monarc (transobturator standard midurethral sling)
Number of subjects: 193
Study: 25899986

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lomustine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Combined lomustine and bevacizumab
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (no treatment specified)
Number of subjects: 138
Study: 24088680

Group type: EXPERIMENTAL
Intervention: Nevirapine-containing ART
Number of subjects: 402

Group type: COMPARATOR
Intervention: Non-ART (control)
Number of subjects: 402
Study: 20527137

Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate 0.1% in lipocream (HCB 0.1% LCr)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Lipocream alone (LCr)
Number of subjects: 264
Study: 17586038

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA) materials
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: MTA materials
Number of subjects: 156
Study: 16617220

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention based on cognitive behavioral therapy
Number of subjects: 2481

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 2481
Study: 12716076

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Ca‐A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (ACE‐I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist (ARB)
Number of subjects: 0
Study: 11066055

Group type: EXPERIMENTAL
Intervention: Oral chemotherapy with trofosfamide (100 mg/m2) and etoposide (25 mg/m2), daily or for 21-day cycles interrupted by 1-week rests, with concurrent standard fractionated radiation (54 grays).
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group from Surveillance, Epidemiology, and End Results data.
Number of subjects: 22
Study: 8840284

Group type: EXPERIMENTAL
Intervention: Chronic rEPO therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not receiving rEPO therapy
Number of subjects: 30
Study: 1632179

Group type: EXPERIMENTAL
Intervention: Atracurium with or without lidocaine (groups A, B, C)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Succinylcholine (groups F, G)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Atracurium (group B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Succinylcholine only (group F)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lidocaine in combination with atracurium (group D)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Lidocaine in combination with succinylcholine (group G)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 105
Study: 28976210

Group type: EXPERIMENTAL
Intervention: Vigna nakashimae extract (1 g thrice daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo tablets (control group)
Number of subjects: 18
Study: 27233479

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise and education intervention (6 sessions, 2 hours/week)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 74
Study: 24226568

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate, 0.05% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hydrocortisone, 1% cream applied twice daily for 24 weeks (2 cycles of 6 weeks on, 6 weeks off)
Number of subjects: 41
Study: 22830016

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/d and Tretinoin 10 mg/BID for six months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo and Riluzole
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Active treatment (Pioglitazone and Tretinoin)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Higher levels of pNF-H at baseline
Number of subjects: 27
Study: 20075313

Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Discrimination at school or work
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Discrimination at shops
Number of subjects: 2561

Group type: EXPERIMENTAL
Intervention: Discrimination by police
Number of subjects: 2561
Study: 19128256

Group type: EXPERIMENTAL
Intervention: Biatain Ibu Nonadhesive (foam dressing with ibuprofen)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Biatain Non-Adhesive (foam dressing without ibuprofen)
Number of subjects: 122
Study: 16648092

Group type: EXPERIMENTAL
Intervention: Reflexology treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14665498

Group type: EXPERIMENTAL
Intervention: Guaifenesin (400 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy volunteers (no intervention)
Number of subjects: 28
Study: 11035667

Group type: EXPERIMENTAL
Intervention: European Commission for Steel and Coal questionnaire and spirometry with bronchodilator test
Number of subjects: 4035
Study: 8767350

Group type: EXPERIMENTAL
Intervention: Isradipine monotherapy (n = 32)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combination therapy (Isradipine + metoprolol/enalapril) (n = 11)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (single administration of isradipine 5 mg for responsiveness testing)
Number of subjects: 55
Study: 1623868

Group type: EXPERIMENTAL
Intervention: Prehospital thrombolytic treatment with anistreplase
Number of subjects: 350

Group type: COMPARATOR
Intervention: In-hospital thrombolytic treatment with anistreplase
Number of subjects: 350
Study: 6435272

Group type: EXPERIMENTAL
Intervention: Cefamandole nafate 2 gm administered intravenously preoperatively and 6 hours postoperatively in four doses
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cefamandole nafate 0.4% solution: 250 ml to irrigate the abdominal wound on opening, 500 ml to irrigate the peritoneal cavity, and 250 ml to irrigate the wound on closing
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Systemic plus topical administrations as in Nos. 1 and 2
Number of subjects: 88
Study: 31568000

Group type: EXPERIMENTAL
Intervention: Adjuvant moxibustion therapy with usual care for 12 weeks (24 sessions)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care (acetaminophen on demand and self-directed exercise education)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Adjuvant moxibustion therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 29856274

Group type: EXPERIMENTAL
Intervention: Body Safety Training Program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study: 26883118

Group type: EXPERIMENTAL
Intervention: Wellbeing interventions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Community engagement
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Primary care training
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Community mapping activities and access to wellbeing interventions
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Health practitioner participation in community consultative groups
Number of subjects: 110
Study: 25149070

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 3657

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3657
Study: 22146409

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta‐1a three times a week
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta‐1a once a week
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 19376326

Group type: EXPERIMENTAL
Intervention: BMP risk model
Number of subjects: 279337
Study: 18172677

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) with bilateral LLND and complete PANP
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group with bilateral LLND and limited PANP
Number of subjects: 44

Group type: COMPARATOR
Intervention: Overall and disease-free survival
Number of subjects: 44

Group type: COMPARATOR
Intervention: Local recurrence
Number of subjects: 44
Study: 17057788

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Laser in situ keratomileusis (LASIK)
Number of subjects: 23
Study: 12003177

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) during structured treatment interruptions (STI) of HAART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Structured treatment interruptions (STI) of HAART
Number of subjects: 0
Study: 10090546

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg q.i.d. for the first 3 days and b.i.d. for 7 days)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 7768497

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX) with triptorelin
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Flutamide with triptorelin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 2334391

Group type: EXPERIMENTAL
Intervention: Special dementia day care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Full-time institutional care
Number of subjects: 0
Study: 420752

Group type: EXPERIMENTAL
Intervention: Varying energy and protein intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low protein and energy levels
Number of subjects: 0
Study: 31174993

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80